R T Reilly

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
    R T Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 60:3569-76. 2000
  2. ncbi request reprint Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 2:133-5. 2001
  3. ncbi request reprint OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen
    Satoshi Murata
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 176:974-83. 2006
  4. ncbi request reprint BNP-7787 (BioNumerik/Baxter Oncology/Grelan)
    R Todd Reilly
    The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA
    IDrugs 7:64-9. 2004
  5. ncbi request reprint Proper costimulation of tumor-reactive T lymphocytes may provide a key to unlock their antitumor activity
    R Todd Reilly
    Department of Oncology, The Johns Hopkins School of Medicine Baltimore, Maryland USA
    Cancer Biol Ther 2:587-8. 2003
  6. ncbi request reprint The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 61:880-3. 2001
  7. ncbi request reprint Chemotherapy: friend or foe to cancer vaccines?
    L A Emens
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 3:77-84. 2001
  8. ncbi request reprint Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
    J P Machiels
    The Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Immunology, Baltimore, Maryland 21231, USA
    Cancer Res 61:3689-97. 2001
  9. ncbi request reprint Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    L A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
    Endocr Relat Cancer 12:1-17. 2005
  10. ncbi request reprint Cytokine gene-modified cell-based cancer vaccines
    R Todd Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 69:233-57. 2002

Collaborators

  • E M Jaffee
  • L A Emens
  • George Sgouros
  • Peter S Kim
  • Satoshi Murata
  • Anne M Ercolini
  • Matthew E Wolpoe
  • Todd D Armstrong
  • Brian H Ladle
  • Naveen K Dakappagari
  • Susan E Ivie
  • Eric R Lutz
  • J P Machiels
  • Holly M Smith
  • Stephanie D Allen
  • Jean Pascal H Machiels
  • Pravin T P Kaumaya
  • Joan T Steele
  • Joan G Bieler
  • Sharad Rawale
  • Lukas W Pfannenstiel
  • Kenneth D Lute
  • Elizabeth A Manning
  • Gary Phillips
  • Elizabeth S Garrett
  • F I Okoye
  • D Weintraub
  • A M Ercolini
  • R Y Lei

Detail Information

Publications16

  1. ncbi request reprint HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
    R T Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 60:3569-76. 2000
    ..These transgenic mice provide a spontaneous tumor model for identifying vaccine approaches potent enough to overcome mechanisms of immune tolerance that are likely to exist in patients with cancer...
  2. ncbi request reprint Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Curr Opin Investig Drugs 2:133-5. 2001
    ..This article seeks to explore the notion that a vaccine designed to optimally activate both arms of the immune system may well generate an antitumor immune response greater than the sum of the two individual effector mechanisms alone...
  3. ncbi request reprint OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen
    Satoshi Murata
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 176:974-83. 2006
    ..These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity...
  4. ncbi request reprint BNP-7787 (BioNumerik/Baxter Oncology/Grelan)
    R Todd Reilly
    The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA
    IDrugs 7:64-9. 2004
    ....
  5. ncbi request reprint Proper costimulation of tumor-reactive T lymphocytes may provide a key to unlock their antitumor activity
    R Todd Reilly
    Department of Oncology, The Johns Hopkins School of Medicine Baltimore, Maryland USA
    Cancer Biol Ther 2:587-8. 2003
  6. ncbi request reprint The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
    R T Reilly
    Department of Oncology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 61:880-3. 2001
    ..These data suggest that vaccines optimized to induce maximal T- and B-cell immunity to neu, and possibly to similar putative tumor-rejection antigens, may lead to more potent in vivo antitumor immunity...
  7. ncbi request reprint Chemotherapy: friend or foe to cancer vaccines?
    L A Emens
    Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, MD 21231, USA
    Curr Opin Mol Ther 3:77-84. 2001
    ..These interactions will require thorough preclinical evaluation to maximize the clinical impact of this type of therapeutic cancer vaccine...
  8. ncbi request reprint Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
    J P Machiels
    The Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Immunology, Baltimore, Maryland 21231, USA
    Cancer Res 61:3689-97. 2001
    ..These data provide the immunological rationale for testing immune-modulating doses of chemotherapy in combination with tumor vaccines in patients with cancer...
  9. ncbi request reprint Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
    L A Emens
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 4M90, Baltimore, Maryland 21231 1000, USA
    Endocr Relat Cancer 12:1-17. 2005
    ....
  10. ncbi request reprint Cytokine gene-modified cell-based cancer vaccines
    R Todd Reilly
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 69:233-57. 2002
  11. ncbi request reprint Cancer vaccines in combination with multimodality therapy
    Leisha A Emens
    The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 4M90 Baltimore, Maryland 21231 1000, USA
    Cancer Treat Res 123:227-45. 2005
  12. ncbi request reprint Augmenting the potency of breast cancer vaccines: combined modality immunotherapy
    Leisha A Emens
    Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Breast Dis 20:13-24. 2004
    ..Combined modality immunotherapies should maximize the potency of the antitumor immune response, thereby improving the outcome of breast cancer therapy...
  13. pmc Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs
    Peter S Kim
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
    J Clin Invest 118:1700-11. 2008
    ..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment...
  14. ncbi request reprint Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities
    Naveen K Dakappagari
    Departments of Obstetrics and Gynecology, Integrated Biomedical Sciences Graduate Program, Ohio State Biochemistry Program, Columbus, Ohio 43210, USA
    J Biol Chem 280:54-63. 2005
    ..Such approaches are a prerequisite to the design of effective peptide vaccines...
  15. pmc Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
    Anne M Ercolini
    Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1591-602. 2005
    ....
  16. ncbi request reprint HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
    Matthew E Wolpoe
    Department of Otolaryngology Head and Neck Surgery, Graduate Program in Immunology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Immunol 171:2161-9. 2003
    ..Collectively, these observations suggest that similarly increased efficacy could be obtained by combining neu-targeted vaccination and neu-specific Abs such as trastuzumab (Herceptin) in patients with neu-expressing cancers...